The Latest Cardiac and Vascular News
CAMBRIDGE, Mass.–(BUSINESS WIRE)–TeraRecon, the leader in medical imaging advanced visualization, clinical AI, and workflow automation, today announced updates to its Intuition platform with new best-in-class cardiac magnetic resonance (MR) medical imaging capabilities. These clinical innovations are now available across all deployment models and on the latest cloud infrastructure. “We are […]
LOS GATOS, Calif., Oct. 23, 2024 /PRNewswire/ — Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced today the first-in-human trans-septal implantations using the 28 Fr. (French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved…
Company also named a Finalist in the Fierce Healthcare Innovation Awards OXFORD, England, Oct. 23, 2024 /PRNewswire/ — Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, has been selected a winner of the Digital Health Hub Foundation: Digital…
Next-generation system to be highlighted during a technology innovation session and live case presentation by Professor Jens Erik Nielsen-Kudsk NASHUA, N.H., Oct. 22, 2024 /PRNewswire/ — Conformal Medical, Inc. announced today, the next-generation CLAAS® AcuFORM™ Left Atrial Appendage…
Intravascular Imaging Technology Featuring the World’s Smallest Imaging Catheter Now FDA Cleared for Pre- and Post-Intervention Use. SUDBURY, Mass., Oct. 22, 2024 /PRNewswire/ — Gentuity, LLC, a global leader in advanced intravascular imaging technologies, is pleased to announce that the…
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To register for the event, please click here.
NANJING, China, Oct. 22, 2024 /PRNewswire/ — HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for “Allogeneic Human iPSC-derived cardiomyocytes…
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation’s Annual Meeting taking place October 28-29 in Lisbon, Portugal.
Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at some point during the trial.
MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure.
